Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06591091
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-05
Brief Title:
Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CLIMB
Brief Summary:
The goal of this study is to find out if the antihistamine clemastine can make the white matter in the brain better in older adults with depression The study will also determine whether this improvement can make antidepressant treatment work better reduce depressive symptoms and improve memory and thinking
Detailed Description:
Geriatric depression also known as late-life depression is a type of major depression that affects people who are 60 years old or older It can be difficult to treat and often comes back after treatment It can also lead to problems with memory and thinking Some studies have found that problems with the white matter in the brain can make it harder to treat depression in older adults White matter helps with communication in the brain A new study suggests that a medicine called clemastine might be able to improve the white matter in the brain Clemastine is usually used as an antihistamine but it might also help the brain repair itself The goal of this study is to find out if clemastine can make the white matter in the brain better in older adults with depression The study will also determine whether this improvement can make antidepressant treatment work better reduce depressive symptoms and improve memory and thinking The study will involve two groups of participants One group will receive the standard antidepressant treatment along with a placebo while the other group will receive the standard antidepressant treatment along with clemastine The investigators will compare the effects of these two treatments over a period of 12 weeks The investigators will measure the improvement in white matter using special brain imaging techniques The investigators will also assess the participants mood memory and thinking abilities and keep track of any side effects or problems caused by the treatments Overall this study has the potential to contribute valuable insights into the treatment of geriatric depression alleviate depressive symptoms enhance cognitive function and potentially open up new avenues for future research and therapeutic approaches
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None